Free UK Delivery on orders over £49

Equipalazone Sachets - Apple Flavoured

Item Number: EQUIPALAPP

Equipalazone Sachets - Apple Flavoured - Equipalazone Sachets - Apple Flavoured

Choose Your Options:

  • 32 Sachets

    Usually dispatched on Friday if ordered within 5 hours and 36 minutes

    £ 44.19

  • 100 Sachets

    In Stock

    £ 105.65

Total: £0.00

Choose options to add to basket

 

 


Browse other products from the Equipalazone product range

Description

Equipalazone 1 g Oral Powder - Apple Flavoured

Free flowing white/cream powder for oral administration, containing 1 g micro-encapsulated Phenylbutazone per sachet.

Preservative: Sodium Paracombin 0.15 % w/w

Uses
Equipalazone 1 g Oral Powder is indicated in the treatment of musculoskeletal disorders in horses and ponies where the anti-inflammatory and analgesic properties of Phenylbutazone can offer relief, for example, in lameness associated with osteoarthritic conditions, acute and chronic laminitis, bursitis and carpitis, and in the reduction of post-surgical soft tissue reaction.

Dosage and administration
Dependent on individual response, but as a guide:

Horses: 450 kg (1000 lb) bodyweight:

Two sachets to be administered twice on day one (equivalent to 8.8 mg/kg/day) followed by one sachet twice daily for four days (4.4 mg/kg/day), then one sachet daily or on alternate days sufficient to keep the horse comfortable (2.2 mg/kg/day).

Ponies: 225 kg (500 lb) bodyweight:

One sachet (4.4 mg/kg/day) on alternate days.

Adjust dose according to bodyweight.

Discontinue treatment if no response is evident after four to five days treatment.

For ease of administration, Equipalazone 1 g Oral Powder may be mixed with a small quantity of bran or oats.

Contra-indications, warnings, etc

Treated horses may never be slaughtered for human consumption.

The therapeutic index of Phenylbutazone is low.

Do not exceed the stated dose or the duration of treatment.

Use is contraindicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.

Do not administer other NSAIDs concurrently or within 24 hours of each other.

Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs to produce an increase in non-bound pharmacologically active concentrations, which can lead to toxic effects.

Use in any animal less than six weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided, animals may require a reduced dosage and careful clinical management.

Avoid use in any dehydrated, hypovolaemic or hypotensive animal as there is a risk of increased renal failure.

Concurrent administration of potentially nephrotoxic drugs should be avoided.

It is preferable that NSAIDs which inhibit prostaglandin synthesis are not administered to animals undergoing general anaesthesia until fully recovered.

Use during pregnancy should be avoided whenever possible, particularly during the first trimester.

Response to long-term therapy should be monitored ar regular intervals by a veterinary practitioner.

Operator warnings: The product should be handled with care at all times to reduce the risk of accidental ingestion, skin contact or dust inhalation. If accidental skin or eye contact occurs, the site should be washed immediately with water. If the product is ingested, seek medical advice immediately and show the product packaging.

Advice to doctors: gastric lavage (emesis in children) should be performed urgently. Charcoal haemoperfusion has also been shown to be beneficial. Treatment should then be administered symptomatically.

General precautions: For animal treatment only.

NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infections appropriate concurrent antimicrobial therapy should be instigated.

Withdrawal period: Do not use in animals intended for human consumption.


Pharmaceutical precautions

Do not store above 25°C. Store in a dry place. Keep out of the reach and sight of children.

Disposal: Dispose of any unused product and empty containers in accordance with guidance from your national waste regulation authority.

Legal category

POM-V (previously POM)


Packaging Quantities
Boxes of 32 and 100 sachets.

Further information

The clinical effect of Phenylbutazone can be evident for at least three days following cessation of administration. This should be borne in mind when examining horses for soundness.

Some authorities (including the Jockey Club) regard Phenylbutazone as a “prohibited substance” under the rules of competition. Therefore, use of this product in a competition horse should be in accordance with the recommendations/advice of the relevant competition authorities.

To be supplied only on veterinary prescription.

Veterinary medicinal product authorised for use in UK and Ireland.

Equipalazone 1 g Oral Powder - Apple Flavoured

Free flowing white/cream powder for oral administration, containing 1 g micro-encapsulated Phenylbutazone per sachet.

Preservative: Sodium Paracombin 0.15 % w/w

Uses
Equipalazone 1 g Oral Powder is indicated in the treatment of musculoskeletal disorders in horses and ponies where the anti-inflammatory and analgesic properties of Phenylbutazone can offer relief, for example, in lameness associated with osteoarthritic conditions, acute and chronic laminitis, bursitis and carpitis, and in the reduction of post-surgical soft tissue reaction.

Dosage and administration
Dependent on individual response, but as a guide:

Horses: 450 kg (1000 lb) bodyweight:

Two sachets to be administered twice on day one (equivalent to 8.8 mg/kg/day) followed by one sachet twice daily for four days (4.4 mg/kg/day), then one sachet daily or on alternate days sufficient to keep the horse comfortable (2.2 mg/kg/day).

Ponies: 225 kg (500 lb) bodyweight:

One sachet (4.4 mg/kg/day) on alternate days.

Adjust dose according to bodyweight.

Discontinue treatment if no response is evident after four to five days treatment.

For ease of administration, Equipalazone 1 g Oral Powder may be mixed with a small quantity of bran or oats.

Contra-indications, warnings, etc

Treated horses may never be slaughtered for human consumption.

The therapeutic index of Phenylbutazone is low.

Do not exceed the stated dose or the duration of treatment.

Use is contraindicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.

Do not administer other NSAIDs concurrently or within 24 hours of each other.

Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs to produce an increase in non-bound pharmacologically active concentrations, which can lead to toxic effects.

Use in any animal less than six weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided, animals may require a reduced dosage and careful clinical management.

Avoid use in any dehydrated, hypovolaemic or hypotensive animal as there is a risk of increased renal failure.

Concurrent administration of potentially nephrotoxic drugs should be avoided.

It is preferable that NSAIDs which inhibit prostaglandin synthesis are not administered to animals undergoing general anaesthesia until fully recovered.

Use during pregnancy should be avoided whenever possible, particularly during the first trimester.

Response to long-term therapy should be monitored ar regular intervals by a veterinary practitioner.

Operator warnings: The product should be handled with care at all times to reduce the risk of accidental ingestion, skin contact or dust inhalation. If accidental skin or eye contact occurs, the site should be washed immediately with water. If the product is ingested, seek medical advice immediately and show the product packaging.

Advice to doctors: gastric lavage (emesis in children) should be performed urgently. Charcoal haemoperfusion has also been shown to be beneficial. Treatment should then be administered symptomatically.

General precautions: For animal treatment only.

NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infections appropriate concurrent antimicrobial therapy should be instigated.

Withdrawal period: Do not use in animals intended for human consumption.


Pharmaceutical precautions

Do not store above 25°C. Store in a dry place. Keep out of the reach and sight of children.

Disposal: Dispose of any unused product and empty containers in accordance with guidance from your national waste regulation authority.

Legal category

POM-V (previously POM)


Packaging Quantities
Boxes of 32 and 100 sachets.

Further information

The clinical effect of Phenylbutazone can be evident for at least three days following cessation of administration. This should be borne in mind when examining horses for soundness.

Some authorities (including the Jockey Club) regard Phenylbutazone as a “prohibited substance” under the rules of competition. Therefore, use of this product in a competition horse should be in accordance with the recommendations/advice of the relevant competition authorities.

To be supplied only on veterinary prescription.

Veterinary medicinal product authorised for use in UK and Ireland.

Reviews